In two murine models of B-ALL driven by the oncogenic fusion protein BRC-ABL1 or constitutively active NRASG12D, the loss of PON2 expression impaired disease progression and drastically improved survival duration in transplant recipient mice10. The gene discussed is PON2; the disease is precursor B-cell acute lymphoblastic leukemia.